Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
August 2, 2004
- 1st Qtr Business Results
August 2, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
August 2, 2004
- OTC NEWS IN BRIEF
August 2, 2004
- Ban Lifted on Sale of 371 OTC Drugs by General Retailers
August 2, 2004
- SSP to Concentrate on Self-medication
August 2, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 2, 2004
- BULLETIN
August 2, 2004
- REGULATORY NEWS IN BRIEF
August 2, 2004
- METI to Develop Healthcare Service Industry
August 2, 2004
- Standing at a Critical Crossroads: Mr Shimada of Nippon Kayaku
August 2, 2004
- BUSINESS NEWS IN BRIEF
August 2, 2004
- JPMA to Provide Technology, Assistance in Asia in FY2004
August 2, 2004
- Therapeutic Category of 380 Generics Clarified
August 2, 2004
- GE Makers to Distinguish Themselves from Competitors
August 2, 2004
- Meet the Leaders (35)
August 2, 2004
- WORLD NEWS IN BRIEF
July 26, 2004
- PRESS SEMINAR
July 26, 2004
- 2 WG to Discuss Problems with Drug Distribution: Ryukaikon
July 26, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 26, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…